Clinical Trial Update: Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating daily isoniazid to prevent tuberculosis in infants born to HIV-infected mothers was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection
• Pneumocystis Jirovecii Pneumonia
• Tuberculosis

Drugs mentioned

• ISONIAZID (ISONIAZID)

Snippet

Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Conditions: HIV Infection, Tuberculosis | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2010-10-19